WATCH: Reshaping the rules—recent IP reforms and their impact on Brazil’s pharma market

Brazil’s pharmaceutical IP landscape is shifting fast, and Juliana Neves of Licks unpacks how new reforms, guidelines, and rulings are resetting the strategic ground rules for innovators.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Moderna: BioNTech is claiming work ‘it never did’

MoFo bags IP trial duo with 50 years’ combined experience

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

WATCH: Reshaping the rules—recent IP reforms and their impact on Brazil’s pharma market

More on this story

Editor's picks

Editor's picks

More features